Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced that the ...

The United States Insulin Pump Market is projected to grow from US$ 1.55 billion in 2024 to US$ 2.58 billion in 2033, with a ...

Tandem Diabetes Care, Inc. , a global insulin delivery and diabetes technology company, announced that the t:slim X2 insulin pump, featuring Control-IQ+ automated insulin delivery (AID) technology, is ...

Tandem Diabetes Care (Nasdaq:TNDM) today announced the rollout of its latest automated insulin delivery system integration.

Tandem Diabetes has announced that the t:slim X2 insulin pump, featuring Control-IQ+ automated insulin delivery (AID) technology, is now available with Abbott’s FreeStyle Libre 3 Plus ...

Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) fell 6% in the afternoon session after investor ...

Earlier this year, Tandem Diabetes Care announced a voluntary correction for certain t:slim X2 insulin pumps after identifying a potential defect that could interrupt insulin delivery and pose health ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $19.57, along with a high estimate of $51.00 and a low estimate of $10.35. A 38.75% drop is ...

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. resulting from allegations that ...

Detailed price information for Tandem Diabetes Care (TNDM-Q) from The Globe and Mail including charting and trades.

Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.

LOS ANGELES, Oct. 16, 2025 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces that ...